MX2014015744A - Anticuerpos a-beta de epítopo de terminal c y central. - Google Patents

Anticuerpos a-beta de epítopo de terminal c y central.

Info

Publication number
MX2014015744A
MX2014015744A MX2014015744A MX2014015744A MX2014015744A MX 2014015744 A MX2014015744 A MX 2014015744A MX 2014015744 A MX2014015744 A MX 2014015744A MX 2014015744 A MX2014015744 A MX 2014015744A MX 2014015744 A MX2014015744 A MX 2014015744A
Authority
MX
Mexico
Prior art keywords
antibody
cdr
seq
amino acid
acid sequence
Prior art date
Application number
MX2014015744A
Other languages
English (en)
Spanish (es)
Inventor
Manuel Buttini
Ming Chen
Shyra Gardai
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MX2014015744A publication Critical patent/MX2014015744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2014015744A 2012-07-03 2013-06-18 Anticuerpos a-beta de epítopo de terminal c y central. MX2014015744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667891P 2012-07-03 2012-07-03
PCT/US2013/046399 WO2014007982A2 (en) 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies

Publications (1)

Publication Number Publication Date
MX2014015744A true MX2014015744A (es) 2015-06-05

Family

ID=49882576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015744A MX2014015744A (es) 2012-07-03 2013-06-18 Anticuerpos a-beta de epítopo de terminal c y central.

Country Status (13)

Country Link
US (1) US20150353631A1 (enExample)
EP (1) EP2869846A4 (enExample)
JP (1) JP2015526409A (enExample)
KR (1) KR20150036163A (enExample)
CN (1) CN105579061A (enExample)
AU (1) AU2013287119A1 (enExample)
BR (1) BR112014033066A2 (enExample)
CA (1) CA2877516A1 (enExample)
HK (1) HK1208810A1 (enExample)
IL (1) IL236549A0 (enExample)
MX (1) MX2014015744A (enExample)
RU (1) RU2014153675A (enExample)
WO (1) WO2014007982A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
JP2018534334A (ja) * 2015-11-20 2018-11-22 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド ２−ヘテロアリール置換ベンゾフラン類のための製剤
KR20250057128A (ko) * 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US20130084245A1 (en) * 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
EP2560681A4 (en) * 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY

Also Published As

Publication number Publication date
IL236549A0 (en) 2015-02-26
RU2014153675A (ru) 2016-08-27
CN105579061A (zh) 2016-05-11
KR20150036163A (ko) 2015-04-07
US20150353631A1 (en) 2015-12-10
CA2877516A1 (en) 2014-01-03
BR112014033066A2 (pt) 2017-08-01
JP2015526409A (ja) 2015-09-10
EP2869846A4 (en) 2016-01-13
WO2014007982A3 (en) 2014-04-03
HK1208810A1 (en) 2016-03-18
AU2013287119A1 (en) 2015-01-22
EP2869846A2 (en) 2015-05-13
WO2014007982A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
KR101197839B1 (ko) Ａｐｏｅ 상태에 의존적인 면역치료 요법
MX2014015744A (es) Anticuerpos a-beta de epítopo de terminal c y central.
US9272030B2 (en) Use of tau to monitor immunotherapy
KR20190003647A (ko) 타우 인식 항체
JP2011526240A (ja) 脳アミロイド血管症の予防および治療
US20130084245A1 (en) Pet monitoring of a-beta-directed immunotherapy
KR20190015703A (ko) 타우 인식 항체
JP2014511174A (ja) Ａｐｏｅ免疫療法
JP2014513678A (ja) Ｉｃ３ｂ沈着を伴うタンパク質凝集に関する疾患を治療するための組成物及び方法
AU2016208353B2 (en) Immunotherapy regimes dependent on ApoE status
AU2013209361B2 (en) Immunotherapy regimes dependent on ApoE status
BRPI0823507A2 (pt) Usos de um anticorpo que se liga especificamente a um epítopo de terminal n de abeta e de uma medição de número de cópia de apoe4